Skip to Content

APL-130277 Approval Status

FDA Approved: No
Brand name: APL-130277
Generic name: apomorphine
Dosage form: Sublingual Film
Company: Sunovion Pharmaceuticals Inc.
Treatment for: Parkinson's Disease

APL-130277 (apomorphine sublingual film) is a novel formulation of the approved dopamine agonist apomorphine in development for the on-demand management of OFF episodes associated with Parkinson’s disease (PD).

Development Status and FDA Approval Process for APL-130277

DateArticle
Jan 30, 2019Sunovion Receives Complete Response Letter from FDA for Apomorphine Sublingual Film (APL-130277)
Jun 12, 2018Sunovion Announces FDA Acceptance of New Drug Application for Apomorphine Sublingual Film (APL-130277)

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide